News & Updates
Filter by Specialty:
TiNO-coated stent maintains edge over drug-eluting stent for ACS
The 3-year outcomes of the TIDES-ACS* trial continued to reflect favourable outcomes with the titanium-nitride-oxide (TiNO)-coated bioactive stent compared with a platinum-chromium-based biodegradable-polymer everolimus-eluting stent (EES) for patients with acute coronary syndrome (ACS).
TiNO-coated stent maintains edge over drug-eluting stent for ACS
16 Nov 2021
Statin confers cardioprotection, survival benefit for middle-aged, older diabetics
Statin reduces the risk of cardiovascular disease and mortality in type 2 diabetes, and this beneficial effect is evident among middle-aged and, to a lesser extent, older patients but not among young patients, a study has found.
Statin confers cardioprotection, survival benefit for middle-aged, older diabetics
14 Nov 2021
Medicine uptitration amps up RDN benefit for drug-resistant hypertension
In patients with multidrug-resistant hypertension (HTN), the blood pressure (BP)-lowering benefit of renal denervation (RDN) achieved at 2 months was amplified when a stepped-care medication escalation protocol was added between 2 and 6 months, updates from the RADIANCE-HTN TRIO trial have shown.
Medicine uptitration amps up RDN benefit for drug-resistant hypertension
14 Nov 2021
Noncardiac surgeries up MI risk post-implantation of DES in ACS, SAP patients
In acute coronary syndrome (ACS) and stable angina pectoris (SAP) patients, undergoing surgery within a year after implantation of drug-eluting stent (DES) increases the risk of myocardial infarction (MI) and death, a recent study has found.